Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Active Specific Immunotherapy in Patients With Indolent Lymphoma Using Autologous Lymphoma-Derived Heat Shock Protein-Peptide Complex (HSPPC-96)

NCT00081809 is registered in ClinicalTrials.gov with Agenus Inc. as lead sponsor.

NCT NCT00081809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00081809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Active Specific Immunotherapy in Patients With Indolent Lymphoma Using Autologous Lymphoma-Derived Heat Shock Protein-Peptide Complex (HSPPC-96)
Lead sponsor
Agenus Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2000
Completion date
June 30, 2005
Enrollment
35
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, follicular, lymphoma, small lymphocytic